Veriphi’s first market application is focused on the verification of oncology drugs as an end-of-line check-in at hospital-based compounding pharmacies.

Commencing in hospital pharmacies allows Veriphi to enter the market without requiring medical device compliance approvals and human clinical trials. Thereby accelerating the commercialisation of its solutions and allowing pharmacy customers to achieve a level of safety not possible by conventional means.

Veriphi has spent considerable time and investment developing its analyser for IV drug verification. The analyser, and the know-how gained, is a technological breakthrough recognised by 22 granted global patents, including eight granted US patents.

For more information about Veriphi, please contact:

Greg Shanahan

Managing Director

e. greg.shanahan@veriphi.co.nz

m. +64 274 356 045

Wanting to receive our investor brochure?